Fosun Pharma subsidiary receives notification of drug clinical trial

Fosun Pharma announced that Chongqing Fuchuang Pharmaceuticals Research Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve its FCN-207 tablets to be used in clinical trials for the treatment of hyperuricemia.

Fosun Pharma announced that Chongqing Fuchuang Pharmaceuticals Research Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve its FCN-207 tablets to be used in clinical trials for the treatment of hyperuricemia.

Phase I clinical trial of the new drug will be carried out in the near future.

As of the date of this announcement, drugs with the same target as the new drug have been on sales worldwide, while there are no drugs with independent intellectual property rights and the same target as the new drug in China.

Phase I clinical trials of the new drug are planned to be carried out in China (excluding Hong Kong, Macao and Taiwan) when the conditions are available in the near future.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/20/fosun-pharma-subsidiary-receives-notification-of-drug-clinical-trial/.

Leave a Reply

Please Login to Comment